Quick Order Cart

Cat. No. ARG0583

Slc30a8 Knockout MIN6 Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Pancreas (islets of Langerhans)

  • Disease:

    Insulinoma

  • Gene Species:

    Mus musculus (Mouse)

The Slc30a8 Knockout MIN6 Cell Line is a CRISPR/Cas9-edited knockout cell line of mouse pancreatic beta cells, featuring targeted disruption of the zinc transporter ZnT8. Loss of ZnT8 impairs insulin granule zinc accumulation and insulin maturation, modeling key aspects of type 2 diabetes pathophysiology. This product is ideal for investigating zinc-dependent insulin secretion and screening therapeutic compounds. The MIN6 host cell line retains glucose-responsive insulin secretion, providing a physiologically relevant platform. Slc30a8 knockout disrupts downstream insulin processing without altering upstream glucose sensing, enabling detailed studies using assays such as western blotting, GSIS, and immunofluorescence.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    MIN6

    Age

    13 weeks

    Sex of Donor

    Unknown

    Gene Name

    Slc30a8

    Gene Species

    Mus musculus (Mouse)

    Gene Identifier

    NCBI Gene ID 239436

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The Slc30a8 Knockout MIN6 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the mouse MIN6 insulinoma cell line. It features targeted disruption of the Slc30a8 gene, which encodes the zinc transporter ZnT8, a protein critical for insulin granule zinc transport. This stable, loss-of-function cellular model is designed for studying the molecular mechanisms underlying zinc-dependent insulin maturation, storage, and secretion. The knockout cell line provides a consistent genetic background for reproducible experiments without the variability of primary islet cultures. The MIN6 host cell line is an SV40 T antigen-immortalized mouse pancreatic beta cell line that retains glucose-responsive insulin secretion and key beta cell characteristics. These cells express essential glucose-sensing components, including GLUT2, glucokinase, and KATP channels, and undergo regulated insulin exocytosis in response to physiological glucose levels. Widely used in diabetes research, MIN6 cells offer a homogeneous, expandable model for investigating beta cell function, signal transduction, and metabolic regulation. The immortalized nature ensures long-term culture stability and experimental reproducibility. SLC30A8 encodes ZnT8, a zinc transporter localized to insulin secretory granule membranes. ZnT8 facilitates zinc influx into granules, enabling insulin hexamer crystallization and stable hormone storage. Expression is regulated by key beta cell transcription factors PDX1 and MAFA, as well as by glucose and insulin signaling. Within the insulin secretion pathway, glucose uptake via GLUT2 and metabolism by glucokinase raise the ATP/ADP ratio, closing KATP channels, causing depolarization and calcium influx through voltage-gated calcium channels, which triggers granule exocytosis. ZnT8 directly interacts with insulin and proinsulin; its disruption abolishes granular zinc accumulation, impairing insulin maturation, granule morphology, and glucose-stimulated insulin secretion. In MIN6 cells, Slc30a8 knockout generates a disease-relevant model of impaired insulin secretion and zinc dyshomeostasis. Since these cells maintain glucose-sensing machinery, ZnT8 loss specifically disrupts granule maturation without affecting upstream glucose metabolism. This recapitulates aspects of type 2 diabetes, where SLC30A8 polymorphisms associate with hyperglycemia and impaired glucose tolerance. The knockout cell line permits dissection of zinc-dependent insulin processing, beta cell function, and compensatory mechanisms under metabolic stress. It enables long-term studies of gene-nutrient interactions and therapeutic interventions. This knockout cell line serves a variety of research applications, from diabetes pathophysiology to zinc transporter biology. Key assays include western blotting for ZnT8, glucose-stimulated insulin secretion (GSIS) assays, ELISA for insulin, and immunofluorescence for granule markers. Zinc-specific staining and RNA-seq further enable analysis of zinc distribution and transcriptomic changes. The model is also suited for drug screening targeting insulin secretion or zinc homeostasis in type 2 diabetes. For technical inquiries, please contact Ascent Research.
Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)